Marc Martin Casas, former head of Illumina Ventures Labs, has moved to the US branch of growth equity firm Premji Invest.
Marc Martin Casas has left biotech company Illumina’s corporate venture capital arm for an investor role at growth equity firm Premji Invest.
Illumina hired Casas in 2019 to work at its Illumina Accelerator subsidiary before promoting him to head the unit in San Francisco.
When the accelerator programme was expanded into Illumina Ventures Labs, a fully-fledged venture building operation, in 2023 under CVC unit Illumina Ventures, Casas was appointed US head, later rising to global head at the start of this year.
In his new role Casas will invest in growth-stage companies, typically cutting cheques between $30m and $150m for the US branch of India-headquartered Premji Invest, targeting therapeutics, diagnostics, tools and healthcare services developers.
